View research View latest news Sign up for updates. Metrics details. Stem cells have demonstrated encouraging potential as reparative therapy for patients suffering from post-stroke disability. Reperfusion interventions in the acute phase of stroke have shown significant benefit but are limited by a narrow window of opportunity in which they are beneficial. Thereafter, rehabilitation is the only intervention available. The current review summarises the current evidence for use of stem cell therapies in stroke from early-phase clinical trials. The safety and feasibility of administering different types of stem cell therapies in stroke seem to be reasonably proven. However, the effectiveness needs still to be established through bigger clinical trials with more pragmatic clinical trial designs that address the challenges raised by the heterogeneous nature of stroke per se, as well those due to unique characteristics of stem cells as therapeutic agents.
Stem cell therapy is considered a potential regenerative strategy for patients with neurologic deficits. Studies involving animal models of ischemic stroke have shown that stem cells transplanted into the brain can lead to functional improvement. In addition, several clinical trials of the use of adult stem cells to treat ischemic stroke are ongoing. This review presents the status of our understanding of adult stem cells and results from clinical trials, and introduces ongoing clinical studies of adult stem cell therapy in the field of stroke. Stroke is one of the leading causes of death and physical disability among adults, with one-quarter to half of stroke survivors being left with complete or partial dependence on others. Stem cell therapy is an emerging paradigm in the field of stroke treatment, and is considered a potential regenerative strategy for patients with neurologic deficits. MSCs can migrate to injured brain regions tropism and self-renew, reportedly without inducing carcinogenesis. Sufficient numbers of MSCs can be easily obtained within several weeks of culture expansion. This review presents the status of the current understanding regarding adult stem cells and the results from clinical trials. The most recent advances in preclinical studies are discussed, and ongoing clinical studies of adult stem cell therapy in the field of stroke are described.
Stroke is the main cause of disability and death in the world within neurological diseases. The use of stem cells as a possible cell therapy in stroke has been tested for years. The results obtained from these studies, although conflicting or controversial in some aspects, are promising. In the last few years, the recent development of the induced pluripotent stem cells has opened new possibilities to find new cell therapies against stroke. In this review, we will provide an overview of the state of the art of cell therapy in stroke. We will describe the current situation of the most employed stem cells and the use of induced pluripotent stem cells in stroke pathology. We will also present a summary of the different clinical trials that are being carried out or that already have results on the use of stem cells as a potential therapeutic intervention for stroke. From the moment that the capacity of differentiation and self-renewal of stem cells became known, their use as cell therapy for a wide range of diseases has been considered. The international community has focused on this idea, starting a revolution in the study of stem cells 1.
View research View latest news Sign up for updates. Metrics details. In recent years, clinical trials with stem cells have taken the emerging field in many new directions. While numerous teams continue to refine and expand the role of bone marrow and cord blood stem cells for their vanguard uses in blood and immune disorders, many others are looking to expand the uses of the various types of stem cells found in bone marrow and cord blood, in particular mesenchymal stem cells, to uses beyond those that could be corrected by replacing cells in their own lineage. Early results from these trials have produced mixed results often showing minor or transitory improvements that may be attributed to extracellular factors. More research teams are accelerating the use of other types of adult stem cells, in particular neural stem cells for diseases where beneficial outcome could result from either in-lineage cell replacement or extracellular factors. At the same time, the first three trials using cells derived from pluripotent cells have begun. Peer Review reports. The rapid advance of stem cell clinical trials for a broad spectrum of conditions warrants an update of the review by Trounson [ 1 ]. There has been a rapid surge in clinical trials involving stem cell therapies over the last two to three years and those trials are establishing the clinical pathways for an emergent new medicine.